一种人类双特异性抗体中和了肉毒神经毒素血清型A的抗体
Jiansheng Lu1, Yujia Jiang1, Jiazheng Guo1
1Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Scientific reports
|November 27, 2023
概括
一种新型双特异性抗体,LUZ-A1-A3,提供了对肉毒神经毒素 (BoNT/A) 暴露的强有力的保护. 这种抗体有效地中和BoNT/A,作为预防和治疗的有前途的药物.
科学领域:
- 免疫学 免疫学 免疫学
- 毒理学 毒理学 毒理学
- 生物技术是生物技术.
背景情况:
- 肉毒神经毒素 (BoNT) 是一种极具致命性的生物威胁.
- 目前的抗毒素疗法需要改进以提高疗效.
- 单克隆抗体 (mAbs) 为中和BoNT提供了一个有希望的治疗途径.
研究的目的:
- 构建一个针对BoNT/A.的双特异性抗体 (LUZ-A1-A3).
- 评估LUZ-A1-A3对BoNT/A的中和效能和保护能力.
主要方法:
- 从人类单克隆抗体 (HMAb) A1和A3.3中开发双特异性抗体 (LUZ-A1-A3).
- 对Luz-A1-A3与BoNT/A Hc和L-HN域结合的评估.
- 在小鼠模型中对LUZ-A1-A3进行体内评估,以保护其免受BoNT/A挑战.
主要成果:
- 与单个HMAb或它们的组合相比,LUZ-A1-A3对BoNT/A的中和活性显著更高.
- 在BoNT/A暴露前7天,LUZ-A1-A3在小鼠中提供了有效的保护.
- LUZ-A1-A3表现出强大的治疗能力,在给药后不久中和了BoNT/A的致命剂量.
结论:
- LUZ-A1-A3是一种高效的双特异性抗体,可以中和BoNT/A.
- LUZ-A1-A3显示出作为对BoNT/A.的预防和治疗剂的显著潜力.
- 进一步开发LUZ-A1-A3可以加强对抗肉毒神经毒素威胁的策略.
相关概念视频
Cross-reactivity
31.1K
Overview
31.1K
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
684
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
684
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
431
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
431


